Lead Sponsor

Genentech, Inc.

Age

60 - 89 years

Sex

ALL

Healthy Volunteers

No

•For CFD4870g participants: Previous enrollment and completion (Month 18 visit) of Study CFD4870g without early treatment discontinuation (lampalizumab or sham)
•For GX29455 participants: Previous enrollment and completion (Week 24 visit) of Study GX29455 without early treatment discontinuation (lampalizumab or sham)
•Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging

•Early treatment and/or study discontinuation prior to completion of study CFD4870g (GX01456) and GX29455
•Vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (AMD) in the study eye
•Subfoveal focal laser photocoagulation in the study eye
•Treatment with Visodyne, external-beam radiation therapy, or transpupillary thermotherapy in the study eye
•Intravitreally (ITV) drug delivery (e.g., ITV corticosteroid injection, anti-angiogenic drugs, anticomplement drugs, or device implantation) in the study eye. Lampalizumab in study eye and ranibizumab in either eye are permitted
•Any concurrent ocular or intraocular condition in the study eye that contraindicates the use of an investigational drug or may affect interpretation of the study results or may render the participant at high risk for treatment complications

Related studies

NCT07392255 · Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07230834 · Geographic Atrophy (GA)

NCT07441642 · Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07144137 · Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT06779773 · Geographic Atrophy, Macular Degeneration

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy